Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab

Simply Wall St.05:39

Bristol Myers Squibb (NYSE:BMY) reported interim Phase 3 results for izalontamab brengitecan in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. The bispecific antibody-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641606911?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/25798-main-header/1756252743505","is_english":true,"pubTime":"2026-06-05 05:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641606911","market":"hk","top_or_hot":-1,"title":"Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab","media":"Simply Wall St.","content":"<div>\n<p>Bristol Myers Squibb (NYSE:BMY) reported interim Phase 3 results for izalontamab brengitecan in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. The bispecific antibody-...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-adds-new-late-stage-oncology-opportunit\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 05:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-adds-new-late-stage-oncology-opportunit><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) reported interim Phase 3 results for izalontamab brengitecan in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. The bispecific antibody-...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-adds-new-late-stage-oncology-opportunit\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1291159041.SGD","symbol_name":"CPR Invest - Global Silver Age A2 Acc SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-adds-new-late-stage-oncology-opportunit","article_id":"2641606911","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/25798-main-header/1756252743505"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-adds-new-late-stage-oncology-opportunit","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641606911","pubTimestamp":1780609153,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bristol Myers Squibb (NYSE:BMY) reported interim Phase 3 results for izalontamab brengitecan in advanced triple-negative breast cancer and esophageal squamous cell carcinoma.\nThe bispecific antibody-drug conjugate showed significant improvements in overall survival compared with standard chemotherapy in both trials.\nThe studies also reported meaningful gains in progression-free survival, pointing to a potential new standard of care in these hard-to-treat cancers.\n\nBristol Myers Squibb, a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0237698245.USD":"富达环球地产基金A","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4581":"高盛持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4585":"ETF&股票定投概念","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BMY":"施贵宝","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4559":"巴菲特持仓","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC"},"translate_title":"百时美施贵宝通过Izalontamab增加了新的晚期肿瘤机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1.5},"content_text":"Bristol Myers Squibb (NYSE:BMY) reported interim Phase 3 results for izalontamab brengitecan in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. The bispecific antibody-drug conjugate showed significant improvements in overall survival compared with standard chemotherapy in both trials. The studies also reported meaningful gains in progression-free survival, pointing to a potential new standard of care in these hard-to-treat cancers.  Bristol Myers Squibb, a large global biopharmaceutical company trading as NYSE:BMY, has built its business around oncology, immunology and cardiovascular drugs. The fresh data for izalontamab brengitecan adds a new late-stage asset to an oncology portfolio that already includes approved therapies such as Opdivo and pipeline candidates like mezigdomide in multiple myeloma. For investors tracking recent product news, this trial update sits alongside other pipeline and approval milestones that shape the company’s long-term revenue mix. Looking ahead, investors will likely focus on how regulators, clinicians and treatment guidelines assess these Phase 3 results for izalontamab brengitecan. Key questions revolve around potential filing timelines, the size of eligible patient populations in triple-negative breast cancer and esophageal squamous cell carcinoma, and how any future launch could interact with existing chemotherapy and immunotherapy options in these settings. Stay updated on the most important news stories for Bristol-Myers Squibb by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bristol-Myers Squibb. NYSE:BMY Earnings & Revenue Growth as at Jun 2026 📰 Beyond the headline: 3 risks and 3 things going right for Bristol-Myers Squibb that every investor should see. For Bristol-Myers Squibb, the Phase 3 success of izalontamab brengitecan slots neatly into a broader push to deepen its oncology portfolio as older blockbusters move toward patent expiry. Triple-negative breast cancer and esophageal squamous cell carcinoma are areas with limited effective options, so a therapy that improves both overall survival and progression-free survival versus standard chemotherapy points to a sizeable treatment opportunity if regulators ultimately approve it. Outside China, the drug is being developed jointly with SystImmune, which can help share development costs while giving Bristol-Myers Squibb an additional late-stage solid-tumor asset alongside Opdivo, cell therapies like Breyanzi, and CELMoD agents such as mezigdomide. Against competitors such as Merck, Roche, and AstraZeneca that also focus heavily on oncology, izalontamab brengitecan gives Bristol-Myers Squibb another differentiated mechanism in a crowded field of checkpoint inhibitors and chemotherapy backbones. For investors, the key question is how this potential new standard of care could contribute to future oncology revenues at a time when analysts are already focused on patent cliffs for Eliquis and Opdivo and on whether newer products can carry more of the growth load. AdvertisementHow This Fits Into The Bristol-Myers Squibb Narrative  The strong Phase 3 results support the narrative view that an expanding late-stage oncology pipeline can help offset pressure from upcoming patent expiries by adding additional sources of future revenue. At the same time, analysts in the narrative flag execution risk, and izalontamab brengitecan still needs to move through regulatory review and real-world uptake before it can meaningfully ease concerns about revenue concentration. The narrative focuses heavily on immuno-oncology, targeted protein degradation, and major alliances, while the specific contribution from bispecific antibody-drug conjugates like izalontamab brengitecan is not yet fully reflected.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Bristol-Myers Squibb to help decide what it is worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Even with positive Phase 3 data, regulators could request additional information or limit the eligible population, which may constrain the commercial impact relative to expectations. ⚠️ Analysts have already flagged earnings pressure from patent cliffs, so if pricing, competition from larger oncology players like Merck or Roche, or safety concerns limit izalontamab brengitecan uptake, it may not materially change the longer term risk profile. 🎁 The results add another late-stage oncology asset to a pipeline that already includes CELMoDs, cell therapies, and checkpoint inhibitors, which can diversify the company’s future cancer-treatment mix. 🎁 Success in two difficult solid tumors supports the idea that Bristol-Myers Squibb can continue to bring new mechanisms forward, which may strengthen its competitive position against other large-cap pharma stocks focused on oncology.  What To Watch Going Forward From here, keep an eye on regulatory filings and review timelines for izalontamab brengitecan in both triple-negative breast cancer and esophageal squamous cell carcinoma, as well as any guidance from Bristol-Myers Squibb on how it sees the addressable patient population. Treatment-guideline updates, head-to-head or cross-trial comparisons with other therapies, and early adoption trends will all help show how firmly the drug can establish itself in routine practice. Investors should also watch how management frames this asset, alongside Opdivo and mezigdomide, when discussing the plan to manage Eliquis and Opdivo patent expiries and broader pricing pressure in future earnings calls. To ensure you are always in the loop on how the latest news impacts the investment narrative for Bristol-Myers Squibb, head to the\ncommunity page for Bristol-Myers Squibb to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bristol-Myers Squibb might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641606911","isCrawlerRequest":true}